8.3 C
New York
Thursday, March 28, 2024

Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma

Courtesy of Benzinga.

Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma

Related LGND
Revolade Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder
Cantor Boosts Ligand Pharma Target To $93
United Therapeutics Misses on Q2 Earnings & Revenues – Analyst Blog (Zacks)

In a report rolled out Wednesday, Roth Capital analysts Joseph Pantginis and Assaf Vestin reiterated a Buy rating and $135.00 price target on shares of Ligand Pharmaceuticals Inc. (NASDAQ: LGND), after partner Viking Therapeutics Inc (NASDAQ: VKTX) announced it is moving VK2809, in the next few months, into a Phase II for dyslipidemia fatty liver disease.

The analysts think the recent IPO of Viking and Ligand's considerable stake (about 50 percent) provide long-term upside potential to the latter’s revenue streams. They anticipate that “current revenue streams from partnered products and the broad ‘in development’ portfolio are poised to drive significant growth in the near and longer term.”

On the other hand, Reverend Emmanuel Lemelson of Lemelson Capital Management recently told Benzinga the Viking IPO was not a positive thing. According to the hedge fund manager, by IPOing Viking, Ligand created a "pyramid scheme of shell companies" that has "almost no prospect" of future revenue and earnings with no assets. Sometime into the future, Ligand will be used as a case study into the "excesses of the stock market."

Related Link: Lemelson Doubles Short Position In Ligand Pharmaceuticals, Says It's Created 'Pyramid Scheme Of Shell Companies'

In a recent Benzinga article, “Lemelson argued that Ligand is using its ownership stake to boost its balance sheet with the profits from the IPO being recorded as earnings. Ligand won't record any losses in its P&L from Viking even though the company 'is guaranteed' to show losses in the future, he added.”

In this context, the hedge fund doubled its short position in Ligand, betting against the company — and Roth Capital’s wage. Lemelson added the company isn't building “a real product or business” but is merely an 18-employees firm with a $2 billion market capitalization.

"That's the kind of thing you want to short. It's just not sustainable,” he concluded.

On The Sidelines

Other major Wall Street research firms remain on the sidelines about Ligand. Cantor Fitzgerald analyst Irina Rivkind Koffler recently reiterated a Hold rating on the stock, which seems to be “fairly valued.”

Deutsche Bank analyst Gregg Gilbert also remains cautious. The analyst recently downgraded the stock from Buy to Hold, as the risk/reward profile seems “balanced.”

Latest Ratings for LGND

Date Firm Action From To
Jun 2015 Cantor Fitzgerald Maintains Hold
Jun 2015 Deutsche Bank Downgrades Buy Hold
Mar 2015 Cantor Fitzgerald Maintains Hold

View More Analyst Ratings for LGND
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Short Ideas Health Care Top Stories Analyst Ratings Trading Ideas Best of Benzinga

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,452FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x